Prognostic impact of targetable driver alterations in resected early-stage lung cancer.

ABSTRACT:

Background

Apart from ALK fusions and the common EGFR mutations, targetable molecular alterations are irrelevant for adjuvant treatment decision making in early-stage non-small cell lung cancer (NSCLC). This retrospective analysis aimed to investigate if there is a difference in recurrence-free survival in stage I-III NSCLC harboring druggable molecular alterations compared to subtypes without targetable molecular alterations.

Methods

All consecutive patients who underwent surgery with curative intent for NSCLC (stage I-III) with targetable mutations between January 2015 and December 2020 at three Austrian institutions were identified and compared with tumors without targetable molecular alterations. Tumors with the EGFR-mutated subtype were excluded due

SUBMITTER: Terbuch A 

PROVIDER: S-EPMC11632426 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature